Sylvirene Liquid Wart Corn Callus Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes, after which the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is essential to allow the application to dry fully.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition.

The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes due to the potential for adverse reactions.

Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of complications.

Warnings and Precautions

For external use only, this product must be kept away from fire and flame to prevent any potential hazards.

It is imperative to exercise caution when applying this product. It should not be used on irritated skin or on any area that is infected or reddened. Additionally, it is contraindicated for use on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Patients with diabetes or poor blood circulation should also refrain from using this product.

In the event of accidental ingestion, immediate medical assistance should be sought by contacting the Poison Control Center at 1-800-222-1222.

Should discomfort persist after application, it is advised to discontinue use and consult a healthcare professional for further evaluation and guidance.

Side Effects

Patients should be aware that the product is for external use only and should be kept away from fire and flame to prevent any potential hazards.

In the event that discomfort persists, it is advised that patients stop using the product and consult a doctor for further evaluation and guidance. This recommendation is crucial to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Sylvirene Liquid Wart Corn Callus Remover (salicylic acid 17% liquid wart corn callus remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The available prescribing information does not provide specific data regarding the use of this product during pregnancy. Consequently, the safety concerns, dosage modifications, or special precautions for pregnant patients remain undefined. Healthcare professionals should exercise caution when considering this product for women of childbearing potential and weigh the potential risks against the benefits. It is advisable to discuss any concerns with patients and consider alternative therapies where appropriate.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing this medication to individuals with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, unusual behavioral changes, or any other atypical clinical manifestations.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution, monitor for symptoms, and provide appropriate management in the event of an overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed.

Patients should be informed to avoid contact with the eyes. In the event that the product does come into contact with the eyes, they should flush the eyes with water for at least 15 minutes and seek medical attention if irritation persists.

It is important to emphasize that the product is non-edible. Patients should be instructed to keep the product tightly capped and store it at room temperature, away from heat sources, to ensure safety and efficacy.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, ensuring that it is kept away from excessive heat, specifically temperatures exceeding 37°C (99°F). Proper storage conditions are crucial to maintain the integrity and efficacy of the product.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes; in the event of contact, the eye should be flushed with water for 15 minutes. Additionally, if the product is ingested, patients should seek medical assistance or contact the Poison Control Center immediately at 1-800-222-1222.

No further information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Sylvirene Liquid Wart Corn Callus Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)